Today the National Association of Medicaid Directors sent the attached letter to the leaders of the Senate Finance and HELP and House Energy & Commerce and Ways & Means committees regarding the current situation with break through prescription drug treatments. The letter addresses the challenges presented by new hepatitis C treatments. It focuses on issues pertinent to state Medicaid programs, though it recognizes this issue impacts all government programs and other payers as well as patients. It also calls on Members of Congress to begin a dialogue on break through drug pricing issues and to advance pragmatic solutions that balance the needs of patients and the costs for Medicaid.
- This week the NAMD newsletter welcomes new directors and covers LTSS, national health expenditures, Hill news on CHIP and tax reform, value based purchasing and Medicaid leadership. December 12, 2017
- In the newsletter we cover Opioids, Access Rule guidance, Medicare Part D, NASBO expenditure report and state job opportunities. November 28, 2017
- NAMD newsletter covers our Fall Conference; 1115 waivers; CHIP; Opioids; and State job openings. November 14, 2017